- Home
- ARQT
as 09-18-2025 4:00pm EST
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | WESTLAKE VILLAGE |
| Market Cap: | 2.1B | IPO Year: | 2020 |
| Target Price: | $19.00 | AVG Volume (30 days): | 1.6M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.74 | EPS Growth: | N/A |
| 52 Week Low/High: | $8.03 - $18.15 | Next Earning Date: | 11-05-2025 |
| Revenue: | $263,464,999 | Revenue Growth: | 99.50% |
| Revenue Growth (this year): | 72.46% | Revenue Growth (next year): | 31.69% |
Stock Insider Trading Activity of Arcutis Biotherapeutics Inc. (ARQT)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Watanabe Todd Franklin | ARQT | See Remarks | Sep 9 '25 | Sell | $17.52 | 504 | $8,829.02 | 891,440 | |
| Watanabe Todd Franklin | ARQT | See Remarks | Sep 8 '25 | Sell | $17.54 | 9,625 | $168,799.40 | 891,440 | |
| Matsuda Masaru | ARQT | See Remarks | Sep 4 '25 | Sell | $16.16 | 36,130 | $583,716.28 | 161,234 | |
| Welgus Howard G. | ARQT | Director | Sep 2 '25 | Sell | $15.64 | 10,000 | $156,383.00 | 100,206 | |
| Burnett Patrick | ARQT | See Remarks | Aug 21 '25 | Sell | $15.57 | 2,438 | $37,968.92 | 104,811 | |
| Burnett Patrick | ARQT | See Remarks | Aug 19 '25 | Sell | $16.16 | 1,750 | $28,280.70 | 104,811 | |
| Burnett Patrick | ARQT | See Remarks | Aug 8 '25 | Sell | $14.03 | 3,847 | $53,988.41 | 104,811 |
Latest Arcutis Biotherapeutics Inc. News
ARQT Breaking Stock News: Dive into ARQT Ticker-Specific Updates for Smart Investing
GlobeNewswire
3 days ago
Allure Magazine Honors Arcutis’ ZORYVE® (roflumilast) with Prestigious Best of Beauty Breakthrough Award
Investor's Business Daily
6 days ago
Hims & Hers Leads 15 Growth Stocks Amid Medical Boom
Zacks
7 days ago
Are Medical Stocks Lagging AxoGen (AXGN) This Year?
Insider Monkey
7 days ago
Arcutis Biotherapeutics, Inc. (ARQT) Eyes Pediatric Expansion for ZORYVE Cream
Simply Wall St.
8 days ago
Arcutis Biotherapeutics (ARQT) Surges 31% In Last Quarter
Insider Monkey
9 days ago
Arcutis Biotherapeutics Submits Supplemental New Drug Application to FDA For ZORYVE
GlobeNewswire
13 days ago
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
a month ago
Arcutis to Present at Upcoming Investor Conferences
Compare ARQT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ARQT Arcutis Biotherapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.